Fact CheckerSign in

NCT06671171Completed

Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial

Source: ClinicalTrials.gov · Last updated 4 May 2026

Brief summary (registry, in English)

Wearable health technology, particularly smartwatches, has revolutionized personal health monitoring by enabling continuous, non-invasive tracking of various physiological parameters. The potential applications of these devices in cardiology are extensive, but it is crucial to validate their accuracy against established medical-grade devices. The Apple Watch Series 9 (Apple, USA) exemplifies the capabilities of modern smartwatches, offering a wide range of health tracking features. These include heart rate monitoring, detection of irregular heart rhythms suggestive of atrial fibrillation, electrocardiogram recording, blood oxygen level measurement, and comprehensive mobility metrics (including VO2 max, six-minute walk distance, walking speed, step length, double support time, and walking asymmetry). Many of these parameters are highly relevant for cardiovascular patients, potentially aiding in disease progression monitoring and adverse event prediction. However, there is a lack of comprehensive validation studies for these devices in specific cardiovascular disease populations. This investigator-initiated prospective observational study involving 50-100 participants that aims to validate smartwatchbased assessments using medical-grade devices and techniques. The study will focus on adult patients with congenital heart disease, pulmonary hypertension, heart failure, and coronary artery disease, as well as athletes undergoing cardiovascular assessment. By comparing smartwatch data with established clinical measurements, the investigators seek to determine the reliability and potential clinical utility of these wearable devices in diverse cardiovascular contexts. This research will help bridge the gap between consumer-grade wearable technology and clinical practice in cardiology.

Status (registry)
Completed
Study type
Observational
Enrollment
50 (actual)
First submitted
24 Oct 2024
Start date
3 Feb 2025
Primary completion date
23 Feb 2026
Lead sponsor
The University of Hong Kong
NCT number
NCT06671171

What you commit to

  • Study type: Observational
  • Participants enrolled: 50
  • From 3 Feb 2025 to the primary completion date, 23 Feb 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Known allergy to components of the investigational product

Other

  • Contraindication for undergoing physical exertion including cardio-pulmonary exercise testing (CPX) and 6-minute walk test (6MWT)
  • Pregnancy

Who the study is looking for

  • Age 20 to 70 years old
  • Ability to provide informed consent
  • History of the following cardiovascular conditions
  • Adult congenital heart disease
  • Pulmonary hypertension
  • Heart failure
  • Coronary artery disease
  • Athletes undergoing cardiovascular assessment

Age in the registry: 20 years to 70 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Department of Medicine Queen Marry Hospital
Coordinator of this site? Confirm its status
Hong KongHong Kong SAR ChinaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.